Business Context and Reporting Period
Company: Tharimmune, Inc. (Note: Request metadata listed "Canton Strategic Holdings," but the filing text identifies the registrant as Tharimmune, Inc., trading as THAR on Nasdaq).
Period: Quarterly Report on Form 10-Q for the period ended September 30, 2025.
Business Overview: Tharimmune is a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation. Key programs include TH104 (for chronic pruritus and opioid overdose prophylaxis), TH023 (oral infliximab), and early-stage immuno-oncology candidates (HS1940, HS3215). The company has adopted a Digital Asset Treasury (DAT) strategy involving Canton Coin (CC).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,101,838) | $(6,498,695) | $(8,377,018) |
| Net Loss Per Share (Basic/Diluted) | $(0.34) | $(1.66) | $(7.39) |
| Operating Expenses | $2,093,578 | $6,491,407 | $8,586,328 |
| Cash and Cash Equivalents (Sept 30, 2025) | $7,610,340 | ||
| Total Current Liabilities (Sept 30, 2025) | $1,544,551 | ||
| Accumulated Deficit (Sept 30, 2025) | $(43,399,789) | ||
| Net Cash Used in Operating Activities (YTD) | $(5,686,700) | ||
| Net Cash Provided by Financing Activities (YTD) | $9,737,679 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $2.1 million (24%) for the nine months ended September 30, 2025, compared to the same period in 2024. This was driven primarily by a $2.9 million decrease in Research and Development (R&D) expenses due to reduced pre-clinical vendor costs, license fees, and clinical trial expenditures.
- General and Administrative (G&A): G&A expenses increased by approximately $0.8 million (19%) year-over-year, attributed to higher non-cash stock-based compensation ($0.6 million increase) and investor relations costs.
- Financing Activity: The company significantly increased capital raising activities in 2025 compared to 2024, raising approximately $9.7 million in net proceeds from financing activities in the first nine months of 2025, compared to $1.7 million in 2024.
- Interest Income: Interest income decreased by approximately $0.2 million (92%) year-over-year due to lower cash balances and interest rates.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that prevailing conditions raise substantial doubt about the company's ability to continue as a going concern for at least one year following the report date, citing recurring negative cash flows and the need for substantial additional funding. However, recent financing activities may alter this assessment at year-end.
- Strategic Pivot (Digital Assets): The company has adopted a Digital Asset Treasury strategy, holding Canton Coin (CC). In November 2025 (subsequent to period end), the company closed a "Cryptocurrency Offering" raising approximately $446.2 million in Canton Coin. This introduces significant volatility, regulatory, and custody risks.
- Regulatory Progress: The FDA provided positive feedback on a regulatory pathway for TH104 for opioid overdose prophylaxis (PrHPO), potentially allowing a 505(b)(2) NDA submission without additional clinical trials, though nonclinical toxicology studies are required.
- Executive Changes: Significant leadership changes occurred in November 2025, including the appointment of Mark Wendland as CEO and Mark Toomey as President, alongside substantial cash bonuses approved for executives.
- Risk Factors: Key risks include the volatility of Canton Coin, potential reclassification of CC as a security (which could classify Tharimmune as an investment company), cybersecurity threats to digital assets, and the failure to obtain regulatory approval for product candidates.
Investor Verification Checklist
- Valuation of Canton Coin: Verify the fair value accounting treatment of the $446.2 million Canton Coin holding and the impact of price volatility on future earnings.
- Going Concern Status: Confirm if the company has secured sufficient liquidity to operate beyond the next 12 months given the substantial operating losses.
- Regulatory Pathway for TH104: Monitor the status of the nonclinical toxicology studies required for the PrHPO NDA submission.
- Dilution Impact: Assess the dilution effect from the November 2025 Cash and Cryptocurrency offerings, which involved the issuance of over 170 million shares (cash and pre-funded warrants).
- Executive Compensation: Review the terms of the new employment agreements for the CEO and President, including the $1 million severance provisions and performance bonuses.